NCT01610687 - A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis | Biotech Hunter

Enrollment

137

Participants

Timeline

Start Date

July 31, 2001

Primary Completion Date

February 28, 2005

Study Completion Date

February 28, 2005

Conditions

Multiple SclerosisSpasticity

Interventions

DRUG

GW-1000-02

Contained THC and CBD as extract of Cannabis sativa L. Each 100 μl actuation delivered a dose containing 2.7 mg THC and 2.5mg CBD. The maximum permitted dose was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.

Trial Locations (1)

OX3 7LD

Rivermead Rehabilitation Centre, Oxford